Observational studyClinical research in cardiology : official journal of the German Cardiac Society2026

Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies.

Baseline statin intolerancelooks bad hereHigher discontinuation rates of PCSK9-mAb.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

2.3×

baseline statin intolerance vs no baseline statin intolerance

Bigger than 8 in 10 for adverse events & safety

As reported

HR 2.3, no interval

1,695people with cardiovascular disease, in this paper

Already taking baseline statin intolerance, or nottheir own situation, not assigned

on baseline statin intolerance

not on baseline statin intolerance

Baseline statin intolerance went with higher discontinuation rates of PCSK9-mAb2.3×

correlation, not a test

the abstract, start to end

… with baseline statin intolerance (HR = 2.3, p = 0.012).

← favours treatmentfavours comparator →

could be chance

No interval given · direction only, strength unknown

Discontinuation rates of PCSK9-mAbbaseline statin intolerance vs no baseline statin intolerance

HR 2.3

StatinsAdverse events & safety

1 / 4

2026

this papercites it